{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:14:11Z","timestamp":1788437651447,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vhri.2026.101604","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T20:36:26Z","timestamp":1773347786000},"page":"101604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness of Triple Versus Dual-Drug Therapy for Elimination of Lymphatic Filariasis in India"],"prefix":"10.1016","volume":"55","author":[{"given":"Jeyaram","family":"Kaviya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanjavakam","family":"Sahithya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha Mary","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abdul Khader","family":"Moinudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangisetti Naga Prudhvi","family":"Teja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vhri.2026.101604_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/micc.12031","article-title":"Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis","volume":"20","author":"Chakraborty","year":"2013","journal-title":"Microcirculation"},{"issue":"8","key":"10.1016\/j.vhri.2026.101604_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1473-3099(22)00026-3","article-title":"Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial","volume":"22","author":"Laman","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vhri.2026.101604_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292723","article-title":"Burden of dengue, leishmaniasis and lymphatic filariasis in India and its states from 1990-2019: analysis from the Global Burden of Disease study (GBD 2019)","volume":"18","author":"Dutta","year":"2023","journal-title":"PLOS One"},{"issue":"11","key":"10.1016\/j.vhri.2026.101604_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.pt.2004.08.010","article-title":"Mass drug administration to eliminate lymphatic filariasis in India","volume":"20","author":"Ramaiah","year":"2004","journal-title":"Trends Parasitol"},{"issue":"2","key":"10.1016\/j.vhri.2026.101604_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"Jambulingam","year":"2021","journal-title":"PLOS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.vhri.2026.101604_bib11","first-page":"2","article-title":"Elimination of lymphatic filariasis \u2013 India: updates and way forward","volume":"3","author":"Roy","year":"2018","journal-title":"Manipal J Med Sci"},{"issue":"1","key":"10.1016\/j.vhri.2026.101604_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13071-018-2616-z","article-title":"Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs","volume":"11","author":"Gedge","year":"2018","journal-title":"Parasites Vectors"},{"issue":"12","key":"10.1016\/j.vhri.2026.101604_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011835","article-title":"Cost-effectiveness of vector control strategies for supplementing mass drug administration for eliminating lymphatic filariasis in India","volume":"18","author":"Shepard","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vhri.2026.101604_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vhri.2026.101604_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001984","volume":"7","author":"Stolk","year":"2013","journal-title":"PLOS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vhri.2026.101604_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vhri.2026.101604_bib20","article-title":"dollars in 2023. The U.S. dollar has lost 34% its value since 2009","year":"2009","journal-title":"Inflation Calculator"},{"key":"10.1016\/j.vhri.2026.101604_bib22","series-title":"Lymphatic filariasis interactive visuals","year":"2025"},{"key":"10.1016\/j.vhri.2026.101604_bib24","author":"Kapa"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:22:24Z","timestamp":1788434544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992600018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":14,"alternative-id":["S221210992600018X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101604","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Triple Versus Dual-Drug Therapy for Elimination of Lymphatic Filariasis in India","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101604"}}